These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8861521)

  • 1. Stool markers for colorectal cancer screening: future considerations.
    Ahlquist DA; Gilbert JA
    Dig Dis; 1996; 14(3):132-44. PubMed ID: 8861521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.
    Tibble J; Sigthorsson G; Foster R; Sherwood R; Fagerhol M; Bjarnason I
    Gut; 2001 Sep; 49(3):402-8. PubMed ID: 11511563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin.
    Gilbert JA; Ahlquist DA; Mahoney DW; Zinsmeister AR; Rubin J; Ellefson RD
    Scand J Gastroenterol; 1996 Oct; 31(10):1001-5. PubMed ID: 8898421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
    Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
    Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics.
    Kristinsson J; Armbruster CH; Ugstad M; Kriwanek S; Nygaard K; Tøn H; Fuglerud P
    Scand J Gastroenterol; 2001 Feb; 36(2):202-7. PubMed ID: 11252414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers.
    Karl J; Wild N; Tacke M; Andres H; Garczarek U; Rollinger W; Zolg W
    Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1122-8. PubMed ID: 18928937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faecal calprotectin levels in a high risk population for colorectal neoplasia.
    Kronborg O; Ugstad M; Fuglerud P; Johne B; Hardcastle J; Scholefield JH; Vellacott K; Moshakis V; Reynolds JR
    Gut; 2000 Jun; 46(6):795-800. PubMed ID: 10807890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II.
    Kristinsson J; Nygaard K; Aadland E; Barstad S; Sauar J; Hofstad B; Stray N; Stallemo A; Haug B; Ugstad M; Tøn H; Fuglerud P
    Digestion; 2001; 64(2):104-10. PubMed ID: 11684824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method.
    Johne B; Kronborg O; Tøn HI; Kristinsson J; Fuglerud P
    Scand J Gastroenterol; 2001 Mar; 36(3):291-6. PubMed ID: 11305517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification and integrity analysis of DNA in the stool of colorectal cancer patients may represent a complex alternative to fecal occult blood testing.
    de Kok JB
    Clin Chem; 2003 Dec; 49(12):2112-3. PubMed ID: 14633900
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.
    Duffy MJ; van Rossum LG; van Turenhout ST; Malminiemi O; Sturgeon C; Lamerz R; Nicolini A; Haglund C; Holubec L; Fraser CG; Halloran SP
    Int J Cancer; 2011 Jan; 128(1):3-11. PubMed ID: 20824704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of colorectal findings for cancer prevention by immunochemical stool test with different sensitivity levels].
    Brenner G; Faure H; Heuer S; Reinholz J
    Z Gastroenterol; 2012 Oct; 50(10):1083-8. PubMed ID: 23059801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stool test for colorectal cancer screening--it's time to move!
    Loitsch SM; Shastri Y; Stein J
    Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Faecal calprotectin levels and colorectal neoplasia.
    Brydon WG; Campbell SS; Anderson NA; Wilson RG; Ghosh S
    Gut; 2001 Apr; 48(4):579-80. PubMed ID: 11288736
    [No Abstract]   [Full Text] [Related]  

  • 16. Is fecal calprotectin the next standard in inflammatory bowel disease activity tests?
    Alic M
    Am J Gastroenterol; 1999 Nov; 94(11):3370-1. PubMed ID: 10566749
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular markers for colorectal cancer screening.
    Dickinson BT; Kisiel J; Ahlquist DA; Grady WM
    Gut; 2015 Sep; 64(9):1485-94. PubMed ID: 25994221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The molecular screening of the stool for the colorectal carcinoma].
    Voboril R; Weberová J; Dvorák J
    Rozhl Chir; 2005 Jun; 84(6):281-5. PubMed ID: 16149221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colon cancer screening strategies.
    Agrawal J; Syngal S
    Curr Opin Gastroenterol; 2005 Jan; 21(1):59-63. PubMed ID: 15687886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stool test for colorectal cancer screening: what is going on?
    Bonanno E; Rulli F; Galatà G; Pucci S; Sesti F; Farinon AM; Spagnoli LG
    Surg Oncol; 2007 Dec; 16 Suppl 1():S43-5. PubMed ID: 18055195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.